What disease causes excessive mucus production
Pro Research Analysisby 
Searched over 200M research papers
Diseases Causing Excessive Mucus Production
Excessive mucus production is a hallmark of several respiratory diseases, leading to significant morbidity and mortality. This article explores the primary diseases associated with this symptom and the underlying mechanisms driving mucus overproduction.
Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Asthma and Mucus Hypersecretion
Asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness and mucus overproduction. The cytokine IL-13 plays a crucial role in inducing mucus production in asthma by increasing the number of mucus-producing goblet cells in the airways1 5. This process involves a signaling pathway from chloride channel calcium-activated 1 (CLCA1) to MAPK13, which is responsible for IL-13-driven mucus production1.
COPD and Mucus Accumulation
Chronic Obstructive Pulmonary Disease (COPD) is another major respiratory condition marked by excessive mucus production. In COPD, overproduction and hypersecretion by goblet cells, along with decreased mucus clearance, lead to mucus accumulation. This accumulation affects lung function, quality of life, and increases the risk of exacerbations and hospitalizations8 9. The same CLCA1 to MAPK13 pathway activated in asthma is also highly active in COPD patients, contributing to mucus overproduction1.
Cystic Fibrosis
Cystic Fibrosis (CF) is a genetic disorder that leads to the production of thick, sticky mucus that can clog the airways and lead to severe respiratory issues. The excessive mucus in CF is due to mutations in the CFTR gene, which disrupts chloride and water transport across epithelial cells, resulting in dehydrated and viscous mucus4 6.
Viral Infections
Rhinovirus and Mucus Production
Rhinovirus (RV), a common cause of the common cold, can exacerbate asthma and COPD by inducing mucus overproduction. RV triggers mucin production through a TLR3-EGFR-dependent pathway, which involves the activation of epidermal growth factor receptor (EGFR) signaling2. This pathway leads to increased expression of mucins, particularly MUC5AC, contributing to airway obstruction and disease exacerbation2.
COVID-19 and Mucus Hypersecretion
COVID-19, caused by SARS-CoV-2, has been associated with excessive mucus production, especially in severe cases. Autopsy studies of COVID-19 patients have revealed significant mucus accumulation in the lungs, which can obstruct airways and complicate breathing3. The infection leads to upregulation of mucin genes, including MUC5AC and MUC5B, in the airway epithelial cells, contributing to the formation of a dysfunctional mucus gel3.
Mechanisms of Mucus Overproduction
Inflammatory Pathways
Inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-α) and IL-13 are key drivers of mucus production. TNF-α induces mucus production through an IκB kinase β (IKKβ)-dependent mechanism, which activates NF-κB signaling in airway epithelial cells6 7. This pathway results in increased MUC5AC expression and mucus secretion6.
Environmental and Pathogen Exposure
Chronic exposure to environmental irritants, pathogens, and allergens can lead to a mucus hypersecretory phenotype in diseases like chronic bronchitis and asthma. This response is part of the body's innate defense mechanism but can become detrimental when excessive4 10.
Conclusion
Excessive mucus production is a common feature of several respiratory diseases, including asthma, COPD, cystic fibrosis, and viral infections like COVID-19 and rhinovirus. Understanding the molecular mechanisms behind mucus overproduction, such as the roles of IL-13, TNF-α, and various signaling pathways, is crucial for developing targeted therapies to manage and treat these conditions effectively.
Sources and full results
Most relevant research papers on this topic
IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.
MAPK13 inhibition effectively reduces mucus production in human airway epithelial cells, offering a potential therapeutic approach for inflammatory airway diseases.
In Vitro Study
Rigorous Journal
Highly CitedRhinovirus-induced major airway mucin production involves a novel TLR3-EGFR-dependent pathway.
Rhinovirus-induced mucin production involves a novel TLR3-EGFR-dependent pathway, potentially playing a role in viral-induced airway remodeling and disease exacerbation.
In Vitro StudyHighly CitedSingle-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients
Bronchoalveolar epithelial dysfunction is a key factor in the development of acute respiratory distress syndrome in COVID-19 patients, potentially impacting airway clearance and limiting airflow.
Highly CitedAirway goblet-cell mucus secretion.
Excess mucus production in chronic airways diseases can be detrimental to health, but understanding its development and regulation can lead to successful mucomodulatory strategies.
Highly CitedRegulation of mucin expression in respiratory diseases.
Understanding the origin and processes regulating goblet cell formation in human airway epithelial cells can help identify therapeutic targets for respiratory diseases.
Highly CitedTumor Necrosis Factor-α Triggers Mucus Production in Airway Epithelium through an IκB Kinase β-dependent Mechanism*
IKK plays a crucial role in TNF--mediated mucus production in airway epithelium, which is crucial for respiratory diseases like asthma and cystic fibrosis.
In Vitro StudyHighly CitedTumor necrosis factor-alpha triggers mucus production in airway epithelium through an IkappaB kinase beta-dependent mechanism.
IKKbeta plays a crucial role in TNF-alpha-mediated mucus production in airway epithelium, which is crucial for respiratory diseases like asthma and chronic bronchitis.
In Vitro StudyClinical issues of mucus accumulation in COPD
Mucus accumulation in COPD patients negatively impacts lung function, quality of life, and hospitalizations, and nonpharmacologic treatments include smoking cessation and physical measures.
Rigorous JournalHighly CitedClinical issues of mucus accumulation in COPD
Mucus accumulation in COPD patients negatively impacts lung function, quality of life, and hospitalizations, with nonpharmacologic options including smoking cessation and physical measures.
Rigorous Journal